Polymyositis and dermatomyositis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
| Line 41: | Line 41: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Antigen | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Antigen | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Association | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Association | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Frequency | ||
|- | |- | ||
| rowspan="6" |Antisynthetase | | rowspan="6" |Antisynthetase | ||
| Line 48: | Line 48: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Antisynthetase syndrome | * Antisynthetase syndrome | ||
** Arthritis | |||
** Interstitial lung disease | |||
** Fever | |||
** Mechanic's hands | |||
** Raynaud's phenomenon | |||
* Flare up in spring | * Flare up in spring | ||
* | * Moderate response to treatment | ||
| align="left" style="background:#F5F5F5;" + | | * Poor prognosis | ||
* Associated with epstein-Barr virus (EBV), adenovirus, and influenza infection | |||
| align="left" style="background:#F5F5F5;" + |20-25% | |||
|- | |- | ||
|Anti-PL-7 | |Anti-PL-7 | ||
| Line 81: | Line 88: | ||
| align="left" style="background:#F5F5F5;" + |Chromodomain helicase DNA binding protein 4 | | align="left" style="background:#F5F5F5;" + |Chromodomain helicase DNA binding protein 4 | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* | * Dermatomyositis rash without significant lung involvement | ||
| align="left" style="background:#F5F5F5;" + | | * Acute but mild onset | ||
* Good prognosis | |||
| align="left" style="background:#F5F5F5;" + |5-10% | |||
|- | |- | ||
| | | | ||
| Line 88: | Line 97: | ||
| align="left" style="background:#F5F5F5;" + |Signal recognition particle | | align="left" style="background:#F5F5F5;" + |Signal recognition particle | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cardiac involvement and myalgias | |||
* Flare up in fall | * Flare up in fall | ||
| align="left" style="background:#F5F5F5;" + | | * Very acute and severe onset | ||
* Poor response to treatment | |||
* Very poor prognosis | |||
| align="left" style="background:#F5F5F5;" + |<5% | |||
|- | |- | ||
| | | | ||
Revision as of 18:07, 12 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
|
Polymyositis and dermatomyositis laboratory findings in the news |
|
Blogs on Polymyositis and dermatomyositis laboratory findings |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Different laboratory tests may be used to diagnose polymyositis and dermatomyositis and exclude other myopathies which include:[1][2][3][4][5][6][7]
- Sarcoplasmic enzymes
- Myositis-specific autoantibodies
Sarcoplasmic enzymes
- Sarcoplasmic enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:[8]
- Creatine phosphokinase
- Aldolase
- Transaminases
- Lactic dehydrogenase
Myositis-specific autoantibodies
| Autoantibody | Antigen | Association | Frequency | |
|---|---|---|---|---|
| Antisynthetase | Anti-Jo-1 | Histidyl-tRNA synthetase |
|
20-25% |
| Anti-PL-7 | Threonyl-tRNA synthetase | |||
| Anti PL-12 | Alanyl-tRNA synthetase |
|
||
| Alanyl-tRNA | ||||
| Anti-OJ | Isoleucyl-tRNA synthetase | |||
| Anti-EJ | Glycyl-tRNA synthetase | |||
| Anti Mi-2 | Chromodomain helicase DNA binding protein 4 |
|
5-10% | |
| Anti-SRP | Signal recognition particle |
|
<5% | |
| Anti TIF-1γ antibody | Transcriptional intermediary factor 1-gamma |
|
||
| Anti NXP-2 antibody | Nuclear matrix protein |
|
||
| Anti-SAE antibody | Anti-small ubiquitin-like modifier activating enzyme |
|
||
| Anti HMGCR antibody | 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
|
6% | |
| Others | Anti-FER | Elongation factor 1 alpha | ||
| Anti-KJ | Unidentified cytoplasmic protein | |||
| Anti-MAS | Unidentified cytoplasmic RNA |
References
- ↑ Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
- ↑ Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.
- ↑ Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
- ↑ Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
- ↑ Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
- ↑ Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.